CN104270945B - App特异性bace抑制剂(asbi)及其用途 - Google Patents

App特异性bace抑制剂(asbi)及其用途 Download PDF

Info

Publication number
CN104270945B
CN104270945B CN201380023606.0A CN201380023606A CN104270945B CN 104270945 B CN104270945 B CN 104270945B CN 201380023606 A CN201380023606 A CN 201380023606A CN 104270945 B CN104270945 B CN 104270945B
Authority
CN
China
Prior art keywords
asbi
app
certain embodiments
alzheimer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380023606.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104270945A (zh
Inventor
瓦尔盖斯·约翰
戴尔·E·布雷德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Buck Institute for Research on Aging
Original Assignee
Buck Institute for Research on Aging
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Institute for Research on Aging filed Critical Buck Institute for Research on Aging
Priority to CN201710107804.5A priority Critical patent/CN106902108B/zh
Publication of CN104270945A publication Critical patent/CN104270945A/zh
Application granted granted Critical
Publication of CN104270945B publication Critical patent/CN104270945B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380023606.0A 2012-03-19 2013-03-15 App特异性bace抑制剂(asbi)及其用途 Active CN104270945B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710107804.5A CN106902108B (zh) 2012-03-19 2013-03-15 App特异性bace抑制剂(asbi)及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261612848P 2012-03-19 2012-03-19
US61/612,848 2012-03-19
US201261728688P 2012-11-20 2012-11-20
US61/728,688 2012-11-20
PCT/US2013/032481 WO2013142370A1 (en) 2012-03-19 2013-03-15 APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710107804.5A Division CN106902108B (zh) 2012-03-19 2013-03-15 App特异性bace抑制剂(asbi)及其用途

Publications (2)

Publication Number Publication Date
CN104270945A CN104270945A (zh) 2015-01-07
CN104270945B true CN104270945B (zh) 2017-03-29

Family

ID=49223272

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380023606.0A Active CN104270945B (zh) 2012-03-19 2013-03-15 App特异性bace抑制剂(asbi)及其用途
CN201710107804.5A Active CN106902108B (zh) 2012-03-19 2013-03-15 App特异性bace抑制剂(asbi)及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710107804.5A Active CN106902108B (zh) 2012-03-19 2013-03-15 App特异性bace抑制剂(asbi)及其用途

Country Status (10)

Country Link
US (3) USRE49873E1 (enExample)
EP (2) EP2827711B1 (enExample)
JP (2) JP6482458B2 (enExample)
KR (2) KR102160388B1 (enExample)
CN (2) CN104270945B (enExample)
AU (2) AU2013235422B2 (enExample)
CA (1) CA2867891C (enExample)
DK (1) DK2827711T3 (enExample)
ES (1) ES2745539T3 (enExample)
WO (1) WO2013142370A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49873E1 (en) 2012-03-19 2024-03-19 Buck Institute For Research On Aging APP specific bace inhibitors (ASBIs) and uses thereof
US10729777B2 (en) 2012-04-09 2020-08-04 Case Western Reserve University Compositions and methods for inhibiting the activity of LAR family phosphatases
CN104800200B (zh) * 2014-01-23 2019-04-02 上海中医药大学 高良姜素的医药用途
WO2016072522A1 (ja) * 2014-11-06 2016-05-12 国立大学法人 長崎大学 新規アルツハイマー病治療薬
CA2976258C (en) 2015-02-18 2024-02-20 Buck Institute For Research On Aging Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
CN106474101A (zh) * 2015-06-17 2017-03-08 海南医学院 高良姜素在治疗糖尿病脑病药物中的应用
KR101716571B1 (ko) * 2015-06-19 2017-03-15 단국대학교 천안캠퍼스 산학협력단 알츠하이머성 치매 예방 또는 치료용 약제학적 조성물
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use
WO2018073321A1 (en) * 2016-10-18 2018-04-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis
WO2018226735A1 (en) * 2017-06-05 2018-12-13 Case Western Reserve University Compositions and methods for treating alzheimer's disease
GB2574878A (en) * 2018-06-22 2019-12-25 Biofilm Ltd Oral compositions and mucoadhesive thin films formed therefrom
WO2020051051A1 (en) 2018-09-05 2020-03-12 Case Western Reserve University Methods and compositions for inducing neural plasticity
AU2020395610A1 (en) * 2019-12-06 2022-06-30 Gretals Australia Pty Ltd Neurologically active flavonoid compositions and methods of use thereof
CN111518793A (zh) * 2020-05-20 2020-08-11 谭骏 年轻人血源APPα-分泌酶在阿尔茨海默病中的应用
WO2022035758A1 (en) * 2020-08-12 2022-02-17 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
CN112730839B (zh) * 2021-01-20 2024-01-30 宁波海尔施智造有限公司 一种磁微粒化学发光法测定细胞角蛋白19片段含量的试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649611A (zh) * 2002-04-30 2005-08-03 尤尼根制药公司 作为治疗剂的包含无取代b环类黄酮和黄烷混合物的组合物
US20070191330A1 (en) * 1999-12-30 2007-08-16 Proteotech, Inc. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
CH677886A5 (enExample) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
AU646877B2 (en) 1990-06-15 1994-03-10 Scios Nova Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
DK0971033T3 (da) 1991-01-21 2009-12-14 Elan Pharm Inc Test og model til Alzheimers sygdom
EP0620849B1 (en) 1992-01-07 2003-06-25 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
ATE198622T1 (de) 1993-10-27 2001-01-15 Elan Pharm Inc Transgene tiere, die app allele mit der schwedischen mutation beherbergen
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
FR2730932B1 (fr) 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
AU6383396A (en) 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
FR2742676B1 (fr) 1995-12-21 1998-02-06 Oreal Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie
EP0885192B8 (en) * 1996-01-29 2012-05-16 The United States of America, Represented by the Secretary, Department of Health and Human Services Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
FR2755854B1 (fr) 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
FR2760970B1 (fr) 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
US6492377B1 (en) * 1998-06-25 2002-12-10 Boehringer Ingelheim Pharma Kg Imidazotriazolopyrimidines with adenosine-antagonistic activity
WO2000003819A1 (en) 1998-07-17 2000-01-27 The Penn State Research Foundation Full form roll finishing technique
CN1502696A (zh) 1998-09-24 2004-06-09 �������Ŷ���Լ��������˾ 阿尔茨海默氏疾病分泌酶
FR2787027B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787026B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr) 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr) 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2789076B1 (fr) 1999-02-02 2001-03-02 Synthelabo Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
US7161962B1 (en) 1999-05-27 2007-01-09 Nuera Communications, Inc. Method and apparatus for coding modem signals for transmission over voice networks
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
JP2005503446A (ja) 2001-01-11 2005-02-03 イーストマン ケミカル カンパニー シクロデキストリンスルホネート、ゲスト包接錯体、その製造方法及び関連物質
FR2819427B1 (fr) 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
JP2006512401A (ja) 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
UY26816A1 (es) * 2001-07-04 2003-04-30 Horacio Heinzen Una preparación liposomal de achyrocline satureioides ("marcela"), flavonoides y derivados semisintéticos, para la protección del tejido cerebral frente al dano isquémico- vascular y neurodegenerativo.
US7476393B2 (en) 2002-11-29 2009-01-13 L'oreal Process for the preparation of a cationic nanoemulsion, and cosmetic composition
WO2005014540A1 (en) 2003-08-08 2005-02-17 Schering Corporation Cyclic amine base-1 inhibitors having a heterocyclic substituent
TW200519084A (en) 2003-08-08 2005-06-16 Schering Corp Cyclic amine bace-1 inhibitors having a benzamide substituent
JP2005104850A (ja) 2003-09-26 2005-04-21 Kanazawa Univ Tlo Inc アルツハイマー病の治療薬および予防薬
CN101671307B (zh) 2003-12-15 2014-05-14 默沙东公司 杂环天冬氨酰蛋白酶抑制剂
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7468402B2 (en) 2004-03-17 2008-12-23 Baker Hughes Incorporated Polymeric nanoemulsion as drag reducer for multiphase flow
BRPI0512213A (pt) 2004-06-16 2008-02-19 Wyeth Corp método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
EP1758907B1 (en) 2004-06-16 2009-02-18 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
KR100610562B1 (ko) * 2004-06-28 2006-08-08 재단법인서울대학교산학협력재단 플라보노이드 유도체를 포함하는 급성 또는 만성 퇴행성뇌질환의 예방 또는 치료용 조성물
AR049726A1 (es) 2004-07-22 2006-08-30 Schering Corp Amidas sustituidas inhibidoras de beta secretasa
ES2306200T3 (es) 2004-07-28 2008-11-01 Schering Corporation Inhibidores macrociclicos de beta-secretasa.
CN100441200C (zh) * 2004-11-26 2008-12-10 谢德隆 石杉碱甲、乙复合成分的蛇足石杉提取物及其制备方法
KR20080028881A (ko) 2005-06-14 2008-04-02 쉐링 코포레이션 헤테로사이클릭 아스파르틸 프로테아제 억제제, 이의제조방법 및 용도
AR054620A1 (es) 2005-06-14 2007-07-04 Schering Corp Inhibidores de aspartil proteasas
MX2007016186A (es) 2005-06-14 2008-03-07 Schering Corp Preparacion y uso de inhibidores de proteasas.
EP1902057B1 (en) 2005-06-14 2013-10-23 Merck Sharp & Dohme Corp. Macrocyclic heterocyclic aspartyl protease inhibitors
CA2609582A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
DE602006018456D1 (de) 2005-06-14 2011-01-05 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
MX2007016182A (es) 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasas.
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
EP1896448A1 (en) 2005-06-30 2008-03-12 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
CA2623245A1 (en) 2005-09-26 2007-04-05 Wyeth Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
JP2009513656A (ja) 2005-10-27 2009-04-02 シェーリング コーポレイション 複素環式アスパルチルプロテアーゼインヒビター
PE20070798A1 (es) 2005-10-31 2007-08-24 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas
CN101460480A (zh) 2006-04-05 2009-06-17 阿斯利康(瑞典)有限公司 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途
AU2007258435A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
WO2008011538A2 (en) * 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
WO2008073370A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors containing a tricyclic ring system
US20090041201A1 (en) 2007-08-06 2009-02-12 Carestream Health, Inc. Alignment apparatus for imaging system
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
US9949946B2 (en) 2008-11-11 2018-04-24 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Inclusion complexes of pinocembrin with cyclodextrin or its derivatives
US8466195B2 (en) * 2009-03-13 2013-06-18 Salk Institute For Biological Studies Methods and compositions for treating complications of diabetes and vascular diseases using flavones
CN101543505A (zh) 2009-04-29 2009-09-30 香港科技大学 一种预防和治疗阿尔茨海默氏症的药物及其制备方法
CN103200949B (zh) * 2010-08-10 2016-10-12 香港科技大学 用于治疗神经变性疾病或神经病理性病症的组合物
USRE49873E1 (en) * 2012-03-19 2024-03-19 Buck Institute For Research On Aging APP specific bace inhibitors (ASBIs) and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191330A1 (en) * 1999-12-30 2007-08-16 Proteotech, Inc. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
CN1649611A (zh) * 2002-04-30 2005-08-03 尤尼根制药公司 作为治疗剂的包含无取代b环类黄酮和黄烷混合物的组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Quercetin and rutin exhibit antiamyloidogenic andfi bril-disaggregating effects in vitroand potent antioxidant activity in APPswe cells;Karim Jiménez-Aliaga et al;《Life Sciences》;20111008(第89期);摘要 *
Use of acyl substituents to favour 2,3-epoxidation of 5,7-dioxygenated flavones with dimethyldioxirane;Benjamin J. Compton et al;《Tetrahedron》;20101127(第67期);第718页scheme 1 *

Also Published As

Publication number Publication date
AU2017201599A1 (en) 2017-03-30
US20190298748A1 (en) 2019-10-03
EP2827711A1 (en) 2015-01-28
CA2867891A1 (en) 2013-09-26
JP2015510941A (ja) 2015-04-13
WO2013142370A1 (en) 2013-09-26
KR102073578B1 (ko) 2020-02-05
US20150306122A1 (en) 2015-10-29
CA2867891C (en) 2021-09-14
US10835546B2 (en) 2020-11-17
EP3607946A1 (en) 2020-02-12
ES2745539T3 (es) 2020-03-02
KR20200013807A (ko) 2020-02-07
AU2013235422B2 (en) 2016-12-15
CN106902108A (zh) 2017-06-30
US10357508B2 (en) 2019-07-23
EP2827711B1 (en) 2019-06-19
JP6482458B2 (ja) 2019-03-13
CN104270945A (zh) 2015-01-07
DK2827711T3 (da) 2019-09-23
JP2018035197A (ja) 2018-03-08
USRE49873E1 (en) 2024-03-19
AU2013235422A1 (en) 2014-10-02
EP3607946B1 (en) 2023-02-22
AU2017201599B2 (en) 2018-11-08
KR102160388B1 (ko) 2020-09-28
KR20150002681A (ko) 2015-01-07
CN106902108B (zh) 2020-07-21
EP2827711A4 (en) 2016-03-23

Similar Documents

Publication Publication Date Title
CN104270945B (zh) App特异性bace抑制剂(asbi)及其用途
US11091444B2 (en) Hydantoins that modulate BACE-mediated app processing
CN107709326B (zh) 降低应激诱导的p-tau的三唑并吡啶和三唑并嘧啶

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant